Switzerland’s burgeoning biotech industry continued to gather momentum in 2019 as revenues once again enjoyed healthy year-on-year growth. The Swiss Biotech Report 2020 – to which the Swiss Stock Exchange is a key contributor - provides a comprehensive outlook on the domestic biotech market and showcases some of the game-changing innovations that currently define the sector.
As one of the world’s leading biotech and life sciences stock exchanges – and the listing destination of choice for some of Europe’s largest biotech companies – the Swiss Stock Exchange is an industry thought leader in the sector, and sits on the steering committee of the Swiss Biotech Association. Moreover, Switzerland’s deep investor pool, strong banking system and industry expertise make it an appealing market for biotech firms looking to list.
The Index Outperformer
Conscious of the importance of biotech in Switzerland, the Swiss Stock Exchange developed its own sector-specific index – the Swiss Bio+Medtech Index (SXI) – in 2004 to increase the industry’s visibility. Its excellent track record speaks for itself. The SXI has produced returns of 59% over the last five years, outperforming both the Swiss Performance Index (31%) and the NASDAQ Biotechnology Index (35%). This is indicative of the calibre of the companies listed on the exchange.